XLO — Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 64
- Website: https://www.xiliotx.com
Latest SEC filings for XLO
- S-8 — 2026-08-12
- EFFECT — 2026-06-01
- S-3 — 2026-05-12
- 10-Q — 2026-05-12
- S-3 — 2026-05-12
- 8-K — 2026-05-12
- ARS — 2026-04-28
- 8-K — 2026-04-16
- 3 — 2026-04-16
- S-8 — 2026-03-23
Latest XLO news
- — Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire Inc.)
- — Xilio Therapeutics Appoints Yariv J. Houvras, M.D. (globenewswire.com)
Educational tool only — not investment advice.